Recommendation of the President – Elrexfio (elranatamab)

On 21 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 130/2024 on the appraisal Elrexfio (elranatamab) under the drug program: “Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)”

Publication in Public Information Bulletin (BIP) >>